New combo therapy tested for hard-to-treat colorectal cancer
NCT ID NCT02613650
First seen May 14, 2026 · Last updated Jun 11, 2026 · Updated 5 times
Summary
This early-phase trial tested a combination of two drugs (MEK162 and mFOLFIRI) in 25 adults with advanced RAS-positive colorectal cancer that had stopped responding to standard treatment. The main goal was to find the safest dose and check for side effects. Researchers also looked at whether tumors shrank or stayed stable.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED KRAS POSITIVE METASTATIC COLORECTAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Huntsman Cancer Institute
Salt Lake City, Utah, 84112, United States
Conditions
Explore the condition pages connected to this study.